Albireo Pharma Inc.

44.15-0.1000-0.23%Vol 1.24M1Y Perf 64.99%
Mar 2nd, 2023 16:00 DELAYED
BID44.05 ASK44.60
Open44.90 Previous Close44.25
Pre-Market- After-Market-
 - -  - -%
Target Price
58.00 
Analyst Rating
Moderate Buy 2.43
Potential %
- 
Finscreener Ranking
★+     42.64
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     43.94
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     48.58
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.00 
Earnings Rating
Sell
Market Cap915.85M 
Earnings Date
7th Mar 2023
Alpha0.00 Standard Deviation0.15
Beta0.93 

Today's Price Range

43.9944.90

52W Range

16.0245.23

5 Year PE Ratio Range

-6.00-1.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-
1 Month
-0.23%
3 Months
104.30%
6 Months
128.05%
1 Year
64.99%
3 Years
197.91%
5 Years
35.55%
10 Years
-47.44%

TickerPriceChg.Chg.%
ALBO44.15-0.1000-0.23
AAPL164.902.54001.56
GOOG104.002.68002.65
MSFT289.275.22001.84
XOM109.660.17000.16
WFC37.380.00000.00
JNJ155.001.57001.02
FB196.640.99000.51
GE95.601.55001.65
JPM130.311.56001.21
 
ProfitabilityValueIndustryS&P 500US Markets
95.60
-215.20
-214.50
-484 511.00
-80.90
RevenueValueIndustryS&P 500US Markets
24.87M
1.20
123.61
189.73
Earnings HistoryEstimateReportedSurprise %
Q03 2022-1.86-1.89-1.61
Q02 2022-1.58-2.04-29.11
Q01 2022-2.02-2.19-8.42
Q04 2021-1.27-0.5755.12
Q03 20210.54-1.26-333.33
Q02 2021-1.92-1.901.04
Q01 2021-1.72-2.29-33.14
Q04 2020-1.90-1.3031.58
Earnings Per EndEstimateRevision %Trend
12/2022 QR-1.80-5.26Negative
12/2022 FY-7.861.13Positive
3/2023 QR-1.64-10.81Negative
12/2023 FY-6.58-8.76Negative
Next Report Date-
Estimated EPS Next Report-1.80
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume1.24M
Shares Outstanding20.74K
Shares Float14.72M
Trades Count5.22K
Dollar Volume54.67M
Avg. Volume508.52K
Avg. Weekly Volume508.02K
Avg. Monthly Volume537.74K
Avg. Quarterly Volume479.79K

Albireo Pharma Inc. (NASDAQ: ALBO) stock closed at 44.15 per share at the end of the most recent trading day (a -0.23% change compared to the prior day closing price) with a volume of 1.24M shares and market capitalization of 915.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 90 people. Albireo Pharma Inc. CEO is Ronald H.W. Cooper.

The one-year performance of Albireo Pharma Inc. stock is 64.99%, while year-to-date (YTD) performance is 104.3%. ALBO stock has a five-year performance of 35.55%. Its 52-week range is between 16.02 and 45.23, which gives ALBO stock a 52-week price range ratio of %

Albireo Pharma Inc. currently has a PE ratio of -3.40, a price-to-book (PB) ratio of 4.72, a price-to-sale (PS) ratio of 36.50, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.83%, a ROC of -84.98% and a ROE of -103.26%. The company’s profit margin is -80.90%, its EBITDA margin is -214.50%, and its revenue ttm is $24.87 Million , which makes it $1.20 revenue per share.

Of the last four earnings reports from Albireo Pharma Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.80 for the next earnings report. Albireo Pharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Albireo Pharma Inc. is Moderate Buy (2.43), with a target price of $58, which is 0.00% compared to the current price. The earnings rating for Albireo Pharma Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Albireo Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Albireo Pharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.79, ATR14 : 0.67, CCI20 : 40.16, Chaikin Money Flow : -0.19, MACD : 1.28, Money Flow Index : 21.90, ROC : -0.09, RSI : 68.04, STOCH (14,3) : 52.98, STOCH RSI : 0.05, UO : 45.73, Williams %R : -47.02), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Albireo Pharma Inc. in the last 12-months were: Jan P. Mattsson (Sold 3 892 shares of value $159 481 ), Jason G. Duncan (Sold 3 134 shares of value $101 591 ), Martha Carter (Sold 1 371 shares of value $54 481 ), Michelle Graham (Sold 2 189 shares of value $90 396 ), Pamela Stephenson (Sold 3 564 shares of value $116 947 ), Ronald H.W. Cooper (Sold 3 812 shares of value $117 241 ), Simon Nicolas Reade Harford (Sold 2 462 shares of value $97 916 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (28.57 %)
2 (28.57 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (71.43 %)
5 (71.43 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.43
Moderate Buy
2.43
Strong Buy
1.00

Albireo Pharma Inc.

Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.

CEO: Ronald H.W. Cooper

Telephone: +1 857 254-5555

Address: 10 Post Office Square, South Boston 02109, MA, US

Number of employees: 90

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

65%35%

Bearish Bullish

65%35%


News

Stocktwits